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Abstract: Guanosine, a guanine-based purine nucleoside, has been described as a neuromodulator
that exerts neuroprotective effects in animal and cellular ischemia models. However, guanosine’s
exact mechanism of action and molecular targets have not yet been identified. Here, we aimed
to elucidate a role of adenosine receptors (ARs) in mediating guanosine effects. We investigated
the neuroprotective effects of guanosine in hippocampal slices from A2AR-deficient mice (A2AR−/−)
subjected to oxygen/glucose deprivation (OGD). Next, we assessed guanosine binding at ARs
taking advantage of a fluorescent-selective A2AR antagonist (MRS7396) which could engage in a
bioluminescence resonance energy transfer (BRET) process with NanoLuc-tagged A2AR. Next, we
evaluated functional AR activation by determining cAMP and calcium accumulation. Finally, we
assessed the impact of A1R and A2AR co-expression in guanosine-mediated impedance responses in
living cells. Guanosine prevented the reduction of cellular viability and increased reactive oxygen
species generation induced by OGD in hippocampal slices from wild-type, but not from A2AR−/−
mice. Notably, while guanosine was not able to modify MRS7396 binding to A2AR-expressing cells,
a partial blockade was observed in cells co-expressing A1R and A2AR. The relevance of the A1R
and A2AR interaction in guanosine effects was further substantiated by means of functional assays
(i.e., cAMP and calcium determinations), since guanosine only blocked A2AR agonist-mediated
effects in doubly expressing A1R and A2AR cells. Interestingly, while guanosine did not affect
A1R/A2AR heteromer formation, it reduced A2AR agonist-mediated cell impedance responses. Our
results indicate that guanosine-induced effects may require both A1R and A2AR co-expression, thus
identifying a molecular substrate that may allow fine tuning of guanosine-mediated responses.
Keywords: guanosine; neuroprotection; oxygen/glucose deprivation; NanoBRET; A1R/A2AR heteromer
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1. Introduction
Guanosine is a guanine-based purine nucleoside that has been shown to exert neuroprotective and
neurotrophic effects in both in vitro and in vivo studies (for review, see [1]). Thus, it has been postulated
as a good candidate for the management of several central nervous system (CNS) disorders, including
neurodegenerative diseases (i.e., Parkinson’s, Alzheimer’s) or ischemia [1,2]. Brain ischemia is one of
the major health disability conditions worldwide [3]. It occurs after a blood supply collapse that leads
to a reduced level of oxygen and glucose within the affected brain area. Similarly, upon excitotoxicity
and oxidative stress a failure of cellular bioenergetics occurs [4]. Importantly, a neuroprotective role of
guanosine has been extensively investigated in animal and cellular models of ischemia, excitotoxicity
and oxidative stress [5–10]. Indeed, we have demonstrated that guanosine prevents reactive oxygen
species (ROS) generation and cell death in hippocampal slices subjected to the oxygen/glucose
deprivation (OGD) [11].
The mechanism by which guanosine exerts its neuroprotective effects is still intriguing. Despite
the identification of a putative guanosine binding site in rat brain membranes [12], a specific
guanosine receptor has not yet been discovered. Importantly, it has been hypothesized that
adenosine receptors (ARs) may play a role in mediating guanosine effects, although with some
controversy. For instance, it has been reported that AR selective ligands do not compete for
guanosine binding to rat brain membranes [13,14], whereas AR ligands were able to block some of the
guanosine-dependent neuroprotective effects [15]. In line with this, a selective adenosine A1 receptor
(A1R) antagonist (DPCPX, 8-cyclopentyl-1,3-dipropylxanthine) and a selective A2A receptor (A2AR)
agonist (CGS21680, 2-(4-(2-carboxyethyl)phenethylamino)-5′-N-ethylcarboxamidoadenosine) inhibited
guanosine-mediated neuroprotection in hippocampal slices subjected to OGD [11]. Overall, these
findings, including those using multimodal A1R and A2AR ligand treatments, supported the notion
that both A1R and A2AR would participate in guanosine-mediated effects.
Interestingly, it has been hypothesized that adenosine A1 and A2Areceptor-receptor interactions
(i.e., heteromerization) might be behind some of the guanosine-mediated effects, thus pointing to
the A1R/A2AR heteromer as a putative molecular target for guanosine [16]. Indeed, the existence of
A1R/A2AR heteromers has been demonstrated in presynaptic terminals of striatal neurons controlling
glutamate release [17], thus acting as an adenosine concentration-dependent switch [18]. Consequently,
low to moderate concentrations of adenosine predominantly activate A1R within the A1R/A2AR
heteromer (i.e., inhibiting glutamate release), whereas moderate to high concentrations of adenosine
also activate A2AR, which, by means of the A1R-A2AR intramembrane negative allosteric interaction,
antagonizes A1R function, therefore facilitating glutamate release. Altogether, in view of the already
known experimental indications, the A1R/A2AR heteromer might be viewed as a potential target
for guanosine, thus deserving further attention. Here, we aimed to assess the role of A1R and
A2AR interaction in guanosine-mediated effects. First, we studied the neuroprotective effects of
guanosine in an ex vivo model of brain ischemia, both in wild-type and A2AR deficient (A2AR−/−) mice;
subsequently, we aimed to elucidate, in vitro, both the putative guanosine binding and activation of
the A1R/A2AR heteromer.
2. Materials and Methods
2.1. Chemicals
The ligands used were: adenosine and guanosine from Sigma-Aldrich (St. Louis,
MO, USA); CGS21680 and SCH442416 (2-(2-furyl)-7-[3-(4-methoxyphenyl)propyl]-7H-pyrazolo
[4,3-e]-[1,2,4]triazolo [1,5-c]pyrimidin-5-amine) from Tocris Bioscience (Ellisville, MI, USA). Adenosine
deaminase (ADA) was purchased from Roche Diagnostics (GmbH, Mannheim, Germany) and
zardaverine from Calbiochem (San Diego, CA, USA). MRS7396, which is a selective fluorescent
antagonist at the A2AR derived from SCH442416, was previously described [19].
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2.2. Animals
Wild-type and A2AR−/− CD-1 male and female mice [20] weighing 25–50 g were used at 2–3 months
of age. The University of Barcelona Committee on Animal Use and Care (CEEA-UB) approved the
protocol (Code 10033, 04/02/2018). Animals were housed and tested in compliance with the guidelines
described in the Guide for the Care and Use of Laboratory Animals [21] and following the European
Union directives (2010/63/EU), FELASA and ARRIVE guidelines. Mice were housed in groups of five
in standard cages with ad libitum access to food and water and maintained under a 12-h dark/light
cycle (starting at 7:30 AM), 22 ◦C temperature, and 66% humidity (standard conditions).
2.3. OGD Protocol
Mice were euthanized by cervical dislocation and hippocampi rapidly removed and placed in
an ice-cold Krebs-Ringer bicarbonate buffer (KRB) (composition in mM: 122 NaCl, 3 KCl, 1.2 MgSO4,
1.3 CaCl2, 0.4 KH2PO4, 25 NaHCO3 and 10 d-glucose). The buffer was bubbled with 95% O2/5% CO2
up to pH 7.4. Slices (0.3 mm) were prepared using a Leica VT1200 vibrating blade microtome (Leica,
Wetzlar, Germany) in KRB at 4 ◦C, and one slice per tube was allowed to recover for 30 min in KRB
at 37 ◦C. Control hippocampal slices were incubated until the end of the experiment (15 min plus 2
h) in oxygenated KRB. OGD was induced by incubating the slices for a 15 min period in an OGD
buffer in Hank’s balanced salt solution (HBSS; composition in mM: 1.3 CaCl2, 137 NaCl, 5 KCl, 0.65
MgSO4, 0.3 Na2HPO4, 1.1 KH2PO4, and 5 HEPES), where 10 mM d-glucose was replaced by 10 mM
2-deoxy-glucose and equilibrated with a 95% N2/5% CO2 gas mixture, as described previously [5]
After 15 min of OGD the media of the slices was replaced by oxygenated KRB and maintained for 2 h
for evaluation of cellular viability and ROS generation. Guanosine (100 µM), when present, was added
15 min before (in KRB) and during OGD (in OGD buffer), and maintained in the re-oxygenation period
(2 h), when the OGD buffer was replaced by physiological KRB.
2.4. Cellular Viability Evaluation
For cellular viability assessment, slices were incubated in 0.5 mg/mL 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) for 20 min at 37 ◦C, as previously
described [22]. In brief, the tetrazolium ring of MTT is first cleaved by active dehydrogenases to
produce a precipitated formazan. Then, precipitated formazan can be solubilized with 200 µL of
dimethyl sulfoxide (DMSO) and cellular viability quantified spectrophotometrically at a wavelength of
550 nm by means of a POLARstarplate-reader (BMG Labtech, Durham, NC, USA).
2.5. Measurement of ROS Production
For evaluating ROS generation, slices were incubated with 80 µM 2′,7′-dichlorofluorescein
diacetate (DCFH-DA; Sigma-Aldrich) for 30 min [23]. Then, subsequent to the OGD/reoxygenation
protocol, slices were washed twice with KRB and maintained for 15 min before adding DCFH-DA.
H2DCFDA diffuses through the cell membrane, and it is hydrolyzed by intracellular esterases to the
non-fluorescent form dichlorofluorescin (DCFH). Afterwards, DCFH can react with intracellular H2O2
to form dichlorofluorescein (DCF), a green fluorescent dye. Slices were then transferred to a 96-well
black plate containing 200 µL of KRB, and fluorescence was read (excitation 480 nm, emission 525 nm)
using a POLARStar plate reader (BMG Labtech).
2.6. Plasmid Constructs
The cDNA encoding the human A1R tagged at its N-terminal tail with the O6-alkylguanine-DNA
alkyltransferase (i.e., A1RSNAP) cloned in pRK5 vector (BD PharMingen, San Jose, CA, USA) was a
gift from Prof. Jean-Philippe Pin (CNRS, Montpellier, France). Thus, to perform functional assays
A2ARSNAP [24] and A1RSNAP were used. Also, A2ARRLuc and A1RYFP constructs [17] were used to
perform classical BRET (Bioluminescence Resonance Energy Transfer) assays. Finally, to perform
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NanoBRET experiments with the MRS7396 fluorescent antagonist, we created an A2AR NanoLuc sensor
(A2ARNL). To this end, the cDNA encoding the human A2AR was amplified by polymerase chain reaction
from the pECFP-A2AR vector using the primers: FA2AEco (5′-GCCGGAATTCCCCATCATGGGCTCC
TCGGTGTAC-3′) and RA2ANot (5′-CGCGGCGGCCGCtcaggacactcctgctccatcctggg-3′). The amplified
A2AR insert was then cloned into the EcoRI/NotI sites of pNLF1-secN vector (Promega, Stockholm,
Sweden) containing a hemagglutinin (HA) epitope tag. All the constructs were verified by
DNA sequencing.
2.7. Cell Culture and Transfection
Human embryonic kidney (HEK)-293T cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) (Sigma-Aldrich), supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/mL
streptomycin, 100 mg/mL penicillin and 5% (v/v) fetal bovine serum at 37 ◦C and in an atmosphere
of 5% CO2. HEK-293T cells growing in 60 cm2 plates were transfected with the cDNA encoding the
different plasmids using linear PolyEthylenImine reagent (PEI) (Polysciences Inc., USA).
2.8. NanoBRET Experiments
The NanoBRET assay was performed on stably expressing (A2ARNL) HEK-293T cells, transiently
transfected (or not) with A1RSNAP, according to [25]. In brief, cells were re-suspended in HBSS,
and seeded into poly ornithine coated white 96-well plates. After 24 h, cells were challenged
with/without the non-labelled A2AR antagonist (SCH442416) or guanosine and incubated for 1 h at
37 ◦C. Subsequently, the fluorescent ligand (MRS7396) was added and the plate and returned to 37 ◦C
for 1 h. Finally, coelenterazine-h (Life Technologies Corp.) was added at a final concentration of
5 µM, and readings were performed after 5 min using a CLARIOStar plate reader (BMG Labtech).
The donor and acceptor emissions were measured at 490–510 nm and 650–680 nm, respectively. The
raw NanoBRET ratio was calculated by dividing the 650 nm emission by the 490 nm emission. In
competition studies, results were expressed as a percentage of the maximum signal obtained (mBU;
milliBRET Units).
2.9. cAMP Assay
cAMP accumulation was measured using the LANCE® Ultra cAMP Kit (PerkinElmer, Waltham,
MA, USA) as previously described [26]. In brief, transfected (A2ARSNAP or A2ARSNAP + A1RSNAP)
HEK-293T cells were firstly incubated for 1 h at 37 ◦C with stimulation buffer (BSA 0.1%, ADA
0.5 units/mL, zardaverine 2 µM; in serum-free DMEM) and later on with CGS21680 for 30 min at
37 ◦C. Thereafter, cells were transferred to a 384-well plate in which reagents were added following
manufacturer’s instructions. After 1 h at room temperature, Time-Resolved-Fluorescence Resonance
Energy Transfer (TR-FRET) was determined by measuring light emission at 620 nm and 665 nm by
means of a CLARIOstar plate reader (BMG Labtech).
2.10. Intracellular Calcium Determinations
The A1R-mediated intracellular Ca2+ accumulation was assessed by means of a luciferase
reporter assay based on the expression of the nuclear factor of activated T-cells (NFAT), as previously
described [27]. In brief, cells were transfected with the cDNA encoding the A1R, the NFAT-luciferase
reporter (pGL4-NFAT-RE/luc2p; Promega) and the yellow fluorescent protein (pEYFP-N1; Promega).
After 36 h post-transfection, cells were incubated with the indicated drugs for 6 h. Subsequently,
cells were harvested with passive lysis buffer (Promega), and the luciferase activity of cell extracts
was determined using a luciferase Bright-GloTMassay (Promega) in a POLARStar plate-reader (BMG
Labtech) using a 30-nm bandwidth excitation filter at 535 nm.
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2.11. Label-Free Cellular Impedance Assay
The xCELLigence Real-Time Cell Analyzer (RTCA) system (ACEA Biosciences, San Diego, CA,
USA) was employed to measure changes in cellular impedance correlating with cell spreading and
tightness, thus being widely accepted as a morphological and functional biosensor of cell status [28–30].
Thus, 16-well E-plates (ACEA Biosciences) were coated with 50 µL fibronectin (10 µg/mL) at 37 ◦C for
1 h before being washed three times with 100 µL MilliQ-water before use. The background index for
each well was determined with 90 µL of stimulation buffer (supplemented DMEM with ADA 0.5 U/mL
and zardaverine 10 µM) in the absence of cells. Data from each well were normalized to the time point
just before compound addition using the RTCA software providing the normalized cell index (NCI).
Subsequently, HEK-293T cells permanently expressing the A2ARSNAP construct [31] in the absence or
presence of A1RSNAP (90 µL resuspended in stimulation buffer) were then plated at a cell density of
40,000 cells/well and grown for 18 h in the RTCA SP device station (ACEA Biosciences) at 37 ◦C and in
an atmosphere of 5% CO2 before ligand (i.e., CGS21680 and/or guanosine) addition. Cell index values
were obtained immediately following ligand stimulation every 15 s for a total time of at least 50 min.
For data analysis, the area under the curve (AUC) for each NCI trace response was quantified and
normalized to the basal.
2.12. Statistics
Data are represented as mean ± standard error of mean (SEM). The number of samples/animals (n)
in each experimental condition is indicated in the corresponding figure legend. Comparisons among
experimental groups were performed by Student’s t-test and ANOVA, using GraphPad Prism 6.01
(San Diego, CA, USA), as indicated. Statistical difference was accepted when p < 0.05.
3. Results
3.1. Guanosine-Mediated Neuroprotection in Hippocampal Slices Depends on A2AR Expression
It has been postulated that ARs might be involved in guanosine-mediated responses in vivo [16].
Within this line of inquiry, we first interrogated whether A2AR expression is necessary for
guanosine-mediated neuroprotection, a well-known guanosine effect in vivo [1]. To this end, we
subjected hippocampal slices from wild-type (i.e., A2AR+/+) and A2AR−/− mice to an OGD protocol in
the presence or absence of guanosine. Indeed, significant cell death (p < 0.001) and ROS production
(p = 0.0359) were observed in A2AR+/+ hippocampal slices subjected to the OGD protocol (Figure 1A,B).
Interestingly, guanosine (100 µM) was able to prevent these effects, thus cellular viability significantly
increased (p = 0.0012) and ROS production decreased (p = 0.0389) (Figure 1A,B), as previously
reported [5,11]. Importantly, under the same experimental conditions, in hippocampal slices obtained
from A2AR−/− mice, guanosine failed to prevent OGD-mediated cell death (p = 0.005) and ROS
production (p = 0.0279) (Figure 1A,B), thus losing its neuroprotective effect. Overall, these results
suggested that A2AR expression was necessary for guanosine-mediated neuroprotection.
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Figure 1. Guanosine-mediated neuroprotection in mouse hippocampal slices. Hippocampal slices 
from A2AR+/+ and A2AR−/− mice were subjected to oxygen/glucose deprivation (OGD) in the absence or 
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Figure 1. Guanosine-mediated neuroprotection in mouse hippocampal slices. Hippocampal slices
from A2 R+/+ and A2AR−/− mice were subjected to oxygen/glucose deprivation (OGD) in the absence
or presence of guanosine (100 µM) for 15 min before, and during OGD and re-oxygenation. The cellular
viability (A) was assessed by MTT reduction whereas ROS levels (B) were measured after incorporation
of the DCFDA fluorescent probe. Results were normalized to the control slices (vehicle-treated slices,
dashed line) and expressed as mean ± SEM of three independent experiments performed in triplicate.
The asterisks indicate statistically significant differences (* p <0.05, ** p < 0.01 and *** p < 0.001; one-way
ANOVA with Tukey’s post-hoc test).
3.2. A2AR Ligand Binding is Affected by Guanosine upon A1R Coexpression
Once we demonstrated that the neuroprotective effect of guanosine was A2AR-dependent, we
aimed to assess the putative direct interaction of guanosine with A2AR through ligand binding studies.
To this end, we engineered a fluorescent ligand BRET-based assay to assess A2AR ligand binding in
living cells (Figure 2A). We used a fluorescent A2AR antagonist (MRS7396) that is able to engage in a
BRET process upon interacting with a cell surface A2AR tagged with the NanoLuciferase (NL) at its
N-terminus (i.e., A2ARNL) (Figure 2A). MRS7396 is a BODIPY630/650 derivative of SCH442416 [19],
which upon A2AR binding can act as an acceptor chromophore for NanoLuciferase emission (490 nm)
in a BRET process. Thus, we challenged stable A2ARNL-expressing cells with increasing concentrations
of MRS7396, in the presence/absence of non-labelled SCH442416. Interestingly, a bell-shaped binding
saturation hyperbola, with a KD = 4.8 ± 2.7 nM, was obtained for MRS7396, while in the presence of
a saturating concentration of SCH442416 (1 µM) the binding was displaced (Figure 2B). Our results
showed that the NanoBRET binding assay was a robust and reliable way to assess A2AR ligand binding.
Accordingly, we next assessed possible guanosine effects on A2AR orthosteric binding by performing
a competition assay with a fixed concentration of MRS7396 (10 nM) (occupying ~80% of receptors
at equilibrium) and increasing concentrations of guanosine. Interestingly, under these experimental
conditions, guanosine was unable to alter MRS7396 binding to A2ARNL (Figure 2C), thus indicating
that guanosine does not orthosterically bind to A2AR, as previously reported [12,13].
Since A2AR heteromerizes with A1R [17], and some of the physiological effects of guanosine were
modulated by A1R ligands [32,33], we investigated whether A1R/A2AR heteromer formation affected
AR-related guanosine-dependent effects. To this end, we first recreated the formation of A1R/A2AR
heteromers in HEK-293T cells by transfecting A2ARRLuc and A1RYFP constructs and monitoring
A2AR/A1R heteromerization by a classical BRET approach (Figure A1). Interestingly, neither adenosine
nor guanosine incubation altered A1R/A2AR heteromer formation (Figure A1). Subsequently, we
assessed the impact of A1R co-expression in A2AR binding of MRS7396 using our NanoBRET binding
assay. Notably, in A1R-A2AR doubly expressing cells, guanosine (100 µM) was able to significantly
reduce by 19± 4% (p= 0.0138) the binding of MRS7396 to the A2ARNL, thus indicating that the A1R/A2AR
heteromer might play a potential role in AR-related guanosine-dependent effects (Figure 2C).
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Figure 2. NanoBRET-based A R binding deter inations. (A) Sche atic representation of the
NanoBRET-based assay using A2ARNL stably expressing cells and the fluorescent MRS7396 ligand (red
triangle). When the coelenterazine (Clz) substrate is metabolized by NanoLuciferase (NL), its 475 nm
light emission may engage in a BRET process with MRS7396 given the close proximity (i.e., bound to
A2 RNL). (B) NanoBRET signal for A2 RNL with increasing MRS7396 concentrations in the absence
(solid line) and presence (dotted line) of 1 µM SCH442416. (C) Guanosine (Guo) effects on MRS7396
binding to cells expressing A2ARNL (blue bars) or A2ARNL plus A1RSNAP (red dashed bars). Cells were
incubated with MRS7396 (10 nM) and increasing guanosine concentrations (1–100 µM) in the presence
or absence of 1 µMSCH442416 to allow specific binding calculations. Results were normalized to the
MRS7396 specific binding in the absence of guanosine for each transfection set and expressed as mean
± SEM of four independent experiments performed in triplicate. The asterisks indicate statistically
significant differences * p < 0.05, one-way ANOVA followed by Dunnett’s post-hoc testwhile compared
to control (dashed line).
3.3. A2AR Signalling, but Not A1R, is Modulated by Guanosine in an A1R Coexpression-Dependent Manner
Given that guanosine reduced A2AR binding in an A1R-expression-dependent manner, we
next aimed to determine whether guanosine also impinged into A2AR signaling. Accordingly, we
determined the effects of guanosine in A2AR-mediated cAMP accumulation upon agonist incubation.
In A2AR-expressing cells, the selective A2AR full agonist CGS21680 induced a concentration-dependent
cAMP accumulation (pEC50 = 7.98 ± 0.08), indicating that the receptor was expressed and functional at
the plasma membrane (Figure 3A). Subsequently, we challenged cells with a fixed concentration
of CGS21680 (200 nM) and evaluated the effects of increasing concentrations of guanosine in
A2AR-dependent cAMP accumulation. As shown in Figure 3B, guanosine did not preclude
A2AR-mediated cAMP accumulation. Conversely, in cells doubly expressing A1R and A2AR, guanosine
(100 µM) was able to significantly reduce, by 19 ± 3% (p = 0.0460), the A2AR-mediated cAMP
accumulation (Figure 3B). These results supported the hypothesis that the effects of guanosine might
be dependent on an A1R-A2AR interaction.
Interestingly, our NanoBRET-based binding results and cAMP determinations in the absence and
presence of A1R suggested a direct involvement of this receptor in guanosine-mediated blockade of
A2AR ligand binding and signaling. Thus, to ascertain whether guanosine would directly interact
with A1R we assessed its impact on A1R-dependent signaling. To this end, A1R-mediated calcium
responses in HEK-293T cells were determined through a homogenous bioluminescence reporter
assay system using a NFAT response element controlling luciferase gene expression. While the
activation of A1R, via application of the agonist N6-R-phenylisopropyladenosine (R-PIA, 50 nM),
increased intracellular Ca2+, the incubation with guanosine (100 µM) did not promote intracellular Ca2+
mobilization (Figure 4A). Similarly, when A1R-expressing cells were treated with R-PIA in the presence
of increasing concentrations of guanosine, A1R-dependent intracellular Ca2+ mobilization was not
affected, as observed in doubly A1R and A2AR transfected cells (Figure 4B). Overall, these results
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indicated that guanosine did not interact with A1R, thus ruling out any orthosteric A1R-dependent
trans-inhibition of A2AR function in A1R-A2AR expressing cells.
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Figure 3. A2AR-dependent cAMP accumulation. (A) Concentration-dependent effects of CGS21680 in
cAMP accumulation in singly A2AR expressing cells. The signal was normalized by assigning the 100%
to the maximum signal obtained and 0% to cells without ligand. The data are expressed as the mean ±
SD of a representative experiment performed in triplicate. (B) Guanosine effects on CGS21680-mediated
cAMP accumulation in cells expressing A2ARSNAP (blue bars) or A2ARSNAP plus A1RSNAP (red dashed
bars). Results were normalized to the specific cAMP accumulation in the absence of guanosine for
each transfection set and are expressed as mean ± SEM of four independent experiments performed
in triplicate. The asterisks indicate statistically significant differences * p < 0.05, one-way ANOVA
followed by Dunnett’s post-hoc testwhile compared to control (dashed line).
Finally, we assessed the functional activity of guanosine using the label-free technology. To this
end, the whole-cell guanosine-mediated impedance responses were monitored in living cells expressing
A2AR in the absence or presence of A1R using a biosensor method, as previously reported [34]. First, we
tested CGS21680-mediated changes in morphology (i.e., impedance) of A2ARSNAP expressing HEK-293T
cells, which were recorded in real-time. Interestingly, addition of CGS21680 resulted in a significant
(p = 0.015) increase of impedance, which was blocked by incubation with the selective A2AR antagonist
ZM241385 (Figure 5A,B). In addition, guanosine did not affect the cell basal morphology (p= 0.6105) nor
its CGS218680-mediated changes (p = 0.1217) (Figure 5B). However, in doubly expressing A1R/A2AR
cells guanosine significantly reduced (p < 0.0106) cell basal morphology and precluded (p < 0.0001) the
CGS218680-induced increase in cellular impedance (Figure 5B). Again, these results indicated that the
A1R-A2AR co-expression may play a potential role in AR-related guanosine-dependent cellular effects.
Cells 2019, 8, 1630 9 of 16
Cells2019, 8, x; doi: 8 of 15 
 
Interestingly, our NanoBRET-based binding results and cAMP determinations in the absence 
and presence of A1R suggested a direct involvement of this receptor in guanosine-mediated blockade 
of A2AR ligand binding and signaling. Thus, to ascertain whether guanosine would directly interact 
with A1R we assessed its impact on A1R-dependent signaling. To this end, A1R-mediated calcium 
responses in HEK-293T cells were determined through a homogenous bioluminescence reporter 
assay system using a NFAT response element controlling luciferase gene expression. While the 
activation of A1R, via application of the agonist N6-R-phenylisopropyladenosine (R-PIA, 50 nM), 
increased intracellular Ca2+, the incubation with guanosine (100 µM) did not promote intracellular 
Ca2+ mobilization (Figure 4A). Similarly, when A1R-expressing cells were treated with R-PIA in the 
presence of increasing concentrations of guanosine, A1R-dependent intracellular Ca2+ mobilization 
was not affected, as observed in doubly A1R and A2AR transfected cells (Figure 4B). Overall, these 
results indicated that guanosine did not interact with A1R, thus ruling out any orthosteric A1R-
dependent trans-inhibition of A2AR function in A1R-A2AR expressing cells. 
 
Figure 4. A1R-dependent intracellular Ca2+mobilization. (A) Determination of A1R-mediated 
intracellular calcium accumulation by means of a luciferase reporter assay system. HEK-293T cells 
were transiently transfected with the firefly luciferase-encoding plasmid (pGL4-NFAT-luc2p) and the 
cDNAs encoding the A1RSNAP and the YFP. Thirty-six hours after transfection, cells were treated 6 h 
with the A1R agonist R-PIA (PIA, 50 nM) in the absence or presence of DPCPX (500 nM) or guanosine 
(Guo, 100 µM). Light emission is presented as the percentage increase over basal levels. The data are 
expressed as the mean ± SEM of three independent experiments performed in triplicate. The asterisks 
indicate statistically significant differences *** p < 0.001, one-way ANOVA followed by Dunnett’s 
post-hoc test when compared to control. (B) Guanosine modulation of R-PIA-mediated intracellular 
Ca2+mobilization (PIA-mediated NFAT-Luc induction) in cells expressing A1RSNAP (red bars) or 
A1RSNAP plus A2ARSNAP (blue dashed bars). The dotted line represents the Ca2+ mobilization induced 
by R-PIA in the absence of guanosine within each cell transfection group. The data are expressed as 
the mean ± SEM of three independent experiments performed in triplicate. 
Finally, we assessed the functional activity of guanosine using the label-free technology. To this 
end, the whole-cell guanosine-mediated impedance responses were monitored in living cells 
expressing A2AR in the absence or presence of A1R using a biosensor method, as previously reported 
[34]. First, we tested CGS21680-mediated changes in morphology (i.e., impedance) of A2ARSNAP 
Figure 4. A1R-dependent intracellular Ca2+mobilization. (A) Determination of A1R-mediated
intracellular calcium accumulation by means of a luciferase reporter assay system. HEK-293T cells
were transi ntly tra sfected with the firefly luc rase-encoding plasmid (pGL4-NFAT-luc2p) and the
cDNAs encoding the A1RSNAP and the YF . irty-six hours after transfection, cells were treated 6 h
with the A1R agonist R-PIA (PIA, 50 nM) in the absence or presence of DPCPX (500 nM) or guanosine
(Guo, 100 µM). Light emission is presented as the percentage increase over basal levels. The data are
expressed as the mean ± SEM of three independent experiments performed in triplicate. The asterisks
indicate statisti ally sig ificant ifferences *** p < 0.001, one-way ANOVA followed by Dunnett’s
post-hoc test when compared to control. (B) Guanosine modulation of R-PIA-mediated intracellular
Ca2+mobilization (PIA-mediated NFAT-Luc induction) in cells expressing A1RSNAP (red bars) or
A1RSNAP plus A2ARSNAP (blue dashed bars). The dotted line represents the Ca2+ mobilization induced
by R-PIA in the absence of guanosine within each cell transfection group. The data are expressed as the
mean ± SEM of three independent experiments performed in triplicate.
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4. Discussion
Guanosine is a purine nucleoside with widely demonstrated extracellular neuromodulatory effects
in the CNS, but so far without an identified receptor. Based on the use of selective ligands, ARs have
been proposed as possible targets to explain guanosine-mediated effects in animal and cellular models
of ischemia. However, at present, the mechanism of action of guanosine is not clear. Here, we show
that A2AR expression was crucial for guanosine-mediated protective effects in an ex vivo model of
brain ischemia. In addition, when examining guanosine effects in a controlled heterologous system, we
were able to reveal the importance of a proposed A1R-A2AR interaction mediating guanosine effects,
both in A2AR-ligand binding and in receptor function.
In the OGD ischemia model in hippocampal slices, we previously showed that guanosine induced
a neuroprotective effect (increase of glutamate uptake) that was inhibited by activation of A2AR by
CGS2180 [11]. This effect of CGS21680 in abolishing a guanosine-evoked increase in glutamate uptake
in an OGD protocol was also observed in cultured astrocytes expressing the astrocytic glutamate
transporter Glt-1 [15]. Therefore, here we evaluated guanosine’s neuroprotective effects in A2AR−/−
mice and revealed an important role for this receptor. Thus, in A2AR−/− hippocampal slices, we
observed a loss of the neuroprotective effects of guanosine (increasing viability and controlling ROS
production in OGD conditions) that were observed in slices from wild-type mice (Figure 6A). This result,
consistent with previous data, pointed to ARs as possible targets for guanosine [35,36], prompting us
to further explore the mechanism by which guanosine might act.
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in an A1R-dependent manner. While guanosine does not interfere A1R-depen e t signaling, it
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only in A1R-A2AR co-expressing cells. Therefore, A1R and A2AR may constitute a molecular subs rate
involved in g anosine-mediated effects, but the precise m hanism of action of guanosine involvi g
ARs is still lacking.
Our NanoBRET-based sensor data suggested that, as previously reported [13], guanosine
apparently does not bind directly to the A2AR. However, in A1R/A2AR cells, it was possible to
observe a guanosine-mediated partial displacement of A2AR-ligand binding (Figure 6B). Together
with the ex vivo data, this result would indicate that the mechanism of action of guanosine would
be mediated by this receptor–receptor entity. Indeed, previous data showing both DPCPX- and
pertussis toxin-dependent blockade of protective effects of guanosine in hippocampal slices subjected
Cells 2019, 8, 1630 11 of 16
to OGD [11], supported the dependence on functional A1Rs coupled to a G-protein to mediate
guanosine effects.
We found that guanosine reduced A2AR orthosteric binding only in A1R-A2AR expressing cells.
Thus, we evaluated whether guanosine could modulate A2AR-dependent signaling under the same
experimental conditions. Interestingly, while guanosine did not preclude CGS21680-induced cAMP
accumulation in A2AR-expressing cells, it reduced A2AR-mediated cAMP accumulation in doubly
A1R-A2AR transfected cells, as observed in the ligand-binding assay (Figure 6B). Additionally, the
evaluation of guanosine effects on the functional activity of ARs using the label-free technology
confirmed that guanosine-mediated cell impedance responses were dependent on A1R-A2AR
co-expression. Hence, our results indicate that guanosine could attenuate A2AR signaling (i.e.,
agonist-mediated cAMP accumulation and cell impedance responses) in an A1R-dependent manner
(Figure 6B). On the other hand, when the A1R-dependent signaling (i.e., intracellular Ca2+ mobilization)
was assessed, guanosine was unable to modulate receptor’s function both in singly and doubly
A1R-A2AR transfected cells. Taken together, our results suggest that while guanosine did not signal
through A1R, it requires this receptor to exert its A2AR modulatory effect, which could indicate that
the A1R/A2AR heteromer might be a molecular substrate for guanosine.
The A1R/A2AR heteromer displays some functional characteristics similar to that reported for
other AR-containing oligomers, for instance A2AR combined with the dopamine D2 receptor (D2R) or
the cannabinoid CB1 receptor (CB1R) [37]. Interestingly, these receptor heteromers have been shown
to exert reciprocal receptor-receptor allosteric antagonistic interactions [38]. Precisely, an A1R/A2AR
heteromer-mediated transmembrane-dependent negative allosteric interaction at the ligand-receptor
binding level has been described [39]. In addition, co-activation of both receptors led to a canonical
protein Gs-Gi antagonistic interaction at the level of the adenylyl cyclase [40]. This situation makes it
difficult to conclude whether an effect in a given signaling pathway is caused by either the allosteric or
the canonical interaction. Thus, our data showing that guanosine was able to modulate AR functioning
(i.e., cAMP assay) only in cells expressing A1R and A2AR do not permit a clear determination of the
interaction at the intracellular level (i.e., canonical protein Gs-Gi antagonistic interaction). However,
considering the whole picture, it seems likely that guanosine effects in the physiological context may
depend on the co-expression of both receptors and their and interaction. Indeed, guanosine did not
disrupt the A1R/A2AR heteromer, as observed by a saturable BRET signal, similar to that obtained
following adenosine treatment, and by membrane co-localization of A1R and A2AR in guanosine-treated
cells (Figure A1).
Overall, our data suggest an important role for the A1-A2A receptor–receptor interaction in
guanosine-mediated effects. Thus, while our results seem to rule out an eventual guanosine-mediated
A1R-A2AR canonical antagonistic interaction, further investigation is needed to ascertain whether
guanosine may either modulate the well-known A1R-A2AR allosteric interaction or an indirect
mechanism of action yet to be discovered.
5. Conclusions
In summary, our results revealed that certain AR-related guanosine-mediated effects rely on
A1R and A2AR co-expression. Indeed, in ex vivo experiments, the well-known guanosine-mediated
neuroprotective effect depends on A2AR expression. Thus, guanosine failed to protect A2AR−/− mouse
hippocampal slices from ischemia-induced damage. In addition, while guanosine did not interfere with
A1R-mediated signaling, it modulated A2AR binding and intracellular signaling only in A1R-A2AR
co-expressing cells. Overall, our results suggest that A1R and A2AR may constitute a molecular
substrate involved in guanosine effects, but the precise mechanism of action of guanosine involving
ARs still is intriguing.
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Appendix A
Appendix A.1 Materials and Methods
Appendix A.1.1 Immunocytochemistry
Transfected HEK-293T cells growing on coverslips were fixed in 4% paraformaldehyde for 15
min and exposed to goat anti-A2AR antibody (1 µg/mL; Santa Cruz Biotechnology Inc., Dallas, TX,
USA) plus a rabbit anti-A1R antibody (1 µg/mL; Millipore, Billerica, MA, USA). Primary antibodies
were detected using a Cy3-conjugated donkey anti-goat antibody (1/200; Jackson ImmunoResearch
Laboratories Inc., West Grove, PA, USA) and Cy2-conjugated donkey anti-rabbit antibody (1/200; Jackson
ImmunoResearch Laboratories Inc.). Coverslips were rinsed for 30 min, mounted with Vectashield
immunofluorescence medium (Vector Laboratories, Peterborough, UK) and examined using a Leica
TCS 4D confocal scanning laser microscope (Leica Lasertechnik GmbH, Heidelberg, Germany).
Appendix A.1.2 BRET
BRET saturation experiments were performed as previously described [41]. In brief, HEK-293T
cells were transiently transfected with a constant amount of the A2ARRluc and increasing amounts of
A1RYFP. After 48 h, cells were rapidly washed twice in PBS, detached and resuspended in Hank’s
balanced salt solution buffer (137 mM NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 0.44 mM KH2PO4,
1.3 mM CaCl2, 1.0 mM MgSO4, 4.2 mM NaHCO3, pH 7.4), containing 10 mM glucose. Cell suspensions
were distributed in triplicate into 96-well microplate black plates (Corning, Stockholm, Sweden)
for fluorescence measurement or white plates (Corning 3600) for BRET determination. For BRET
measurement, 5 µM benzyl-coelenterazine (NanoLight Technology, Prolume Ltd., Pinetop, AZ, USA)
was added, and readings were performed 1 min after substrate addition using the POLARstar Omega
plate-reader (BMG Labtech, Durham,NC, USA), which allows the simultaneous integration of the
signals detected with two filter settings [485 nm (440–500 nm) and 530 nm (510–560 nm)]. The BRET
ratio was defined and represented as previously described [41].
Appendix A.2 Results
We aimed to assess whether guanosine treatment modulated the A1R/A2AR heteromerization
status. To this end, we performed immunocytochemistry analyses and constructed classical A1R-A2AR
heteromer-based BRET saturation curves (Figure A1). Our immunocytochemistry experiments revealed
that A2AR and A1R co-distributed in transiently transfected HEK-293T cell, as previously reported [17],
and that 2 h incubation with guanosine did not alter their apparent co-distribution (Figure A1A).
Subsequently, the close proximity of the two receptors was monitored through BRET saturation
analysis in cells transiently expressing A2ARRluc and increasing concentrations of A1RYFPshowing a
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bell-shaped BRET saturation curve (BRET50 = 0.38 ± 0.07 and BRETmax = 90 ± 6), thus indicating the
formation of constitutive A1R-A2AR complexes in living cells (Figure A1B). Importantly, under the
same experimental conditions, the treatment with either adenosine (100 µM) or guanosine (100 µM)
for 2 h did not alter the physical proximity of A1R and A2AR. Thus, neither the BRET50 [F(2,30) = 1.524,
p-value = 0.2343] nor the BRETmax [F(2,30) = 0.3135, p-value = 0.7333] was significantly affected by
adenosine or guanosine incubation (Figure A1B). Overall, these results corroborated the formation
of A1R/A2AR heterocomplexes in living cells, as previously described [17], and that these complexes
were not affected by adenosine or guanosine, consistent with the general notion that GPCR homo- and
heteromerization is often constitutive.Cells2019, 8, x; doi: 13 of 15 
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and incubated with vehicle, adenosine (100 µM) or guanosine (100 µM) for 2 h. Cells were co-
transfected with a fixed amount of A2ARRluc and increasing amounts A1RYFP. Plotted on the X-axis is 
the fluorescence value obtained from the YFP, normalized with the luminescence value of the Rluc 
constructs 10 min after coelenterazine h incubation and in the Y-axis the corresponding BRET ratio (× 
1000). mBU: mBRET units. Results are expressed as mean ± SEM of four independent experiments 
grouped as a function of the amount of acceptor fluorescence. 
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Figure A1. A1R and A2AR interaction in HEK-293T cells. (A) Co-distribution of A2AR and A1R in
HEK-293T. Cells transiently transfected with A2ARSNAP and A1RSNAP and incubated with vehicle
or guanosine (100 µM) for 2 h. Cells were processed for immunocytochemical (ICC) detection of
A2AR (red) and A1R (green) using specific antibodies (see Appendix A.1). Merged images reveal
co-distribution of A2ARSNAP and A1RSNAP (yellow). Scale bar: 100 µm. (B) BRET saturation curve
between A2AR and A1R. BRET was measured in HEK-293T cells co-expressing A2ARRluc and A1RYFP
constructs and incubated with vehicle, adenosine (100 µM) or guanosine (100 µM) for 2 h. Cells were
co-transfected with a fixed amount of A2ARRluc and increasing amounts A1RYFP. Plotted on the X-axis
is the fluorescence value obtained from the YFP, normalized with the luminescence value of the Rluc
constructs 10 min after coelenterazine h incubation and in the Y-axis the corresponding BRET ratio
(×1000). mBU: mBRET units. Results are expressed as mean ± SEM of four independent experiments
grouped as a function of the amount of acceptor fluorescence.
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